



Alkermes to Host Conference Call to Discuss Fiscal Year 2006 Financial Results

May 11, 2006

CAMBRIDGE, Mass., May 11, 2006 (BUSINESS WIRE) -- Alkermes, Inc. (Nasdaq: ALKS) will host a conference call at 4:30 p.m. EDT on Thursday, May 18, 2006 to discuss the Company's financial results for the fiscal year ended March 31, 2006. Management will review the results and provide financial expectations for fiscal year 2007.

The conference call may be accessed by dialing 1-866-847-7861 for domestic callers and 1-703-639-1428 for international callers. The conference call ID number is 902256. Additionally, the call will be webcast on the investor relations section of Alkermes' website at www.alkermes.com and archived on the site until Tuesday, May 23, 2006 at 5:00 p.m. EDT. Alkermes is also providing a podcast MP3 file available for download on the Alkermes website. The podcast will be available from 7:30 p.m. on May 19, 2006 through 5:00 p.m. EDT on May 26, 2006.

A replay of the conference call will be available from 7:30 p.m. EDT on May 18, 2006 through 5:00 p.m. EDT on May 23, 2006, and may be accessed by visiting Alkermes' website or by dialing 1-888-266-2081 for domestic callers and 1-703-925-2533 for international callers. The replay access code is 902256.

Alkermes, Inc. is a pharmaceutical company that develops products based on sophisticated drug delivery technologies to enhance therapeutic outcomes in major diseases. The Company has two commercial products. RISPERDAL(R) CONSTA(R) ((risperidone) long-acting injection), the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, is marketed worldwide by Janssen-Cilag (Janssen), a wholly owned division of Johnson & Johnson. VIVITROL(TM) (naltrexone for extended-release injectable suspension) is the first and only once-monthly injectable medication approved for the treatment of alcohol dependence. The Company has a pipeline of extended-release injectable products and pulmonary drug products based on its proprietary technology and expertise. Alkermes' product development strategy is twofold: the Company partners its proprietary technology systems and drug delivery expertise with several of the world's finest pharmaceutical companies; and it also develops novel, proprietary drug candidates for its own account. The Company's headquarters are in Cambridge, Massachusetts, and it operates research and manufacturing facilities in Massachusetts and Ohio.

SOURCE: Alkermes, Inc.

Alkermes, Inc.
Debra Koufos, 617-583-6220
Associate, Corporate Communications